158 related articles for article (PubMed ID: 19127256)
1. Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours.
Campone M; Levy V; Bourbouloux E; Berton Rigaud D; Bootle D; Dutreix C; Zoellner U; Shand N; Calvo F; Raymond E
Br J Cancer; 2009 Jan; 100(2):315-21. PubMed ID: 19127256
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.
Deenen MJ; Klümpen HJ; Richel DJ; Sparidans RW; Weterman MJ; Beijnen JH; Schellens JH; Wilmink JW
Invest New Drugs; 2012 Aug; 30(4):1557-65. PubMed ID: 21809026
[TBL] [Abstract][Full Text] [Related]
3. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
4. A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer.
Sun JM; Kim JR; Do IG; Lee SY; Lee J; Choi YL; Ahn JS; Ahn MJ; Park K
Br J Cancer; 2013 Sep; 109(6):1482-7. PubMed ID: 23963141
[TBL] [Abstract][Full Text] [Related]
5. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
Quek R; Wang Q; Morgan JA; Shapiro GI; Butrynski JE; Ramaiya N; Huftalen T; Jederlinic N; Manola J; Wagner AJ; Demetri GD; George S
Clin Cancer Res; 2011 Feb; 17(4):871-9. PubMed ID: 21177764
[TBL] [Abstract][Full Text] [Related]
6. Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors.
Abu-Khalaf MM; Baumgart MA; Gettinger SN; Doddamane I; Tuck DP; Hou S; Chen N; Sullivan C; Lezon-Geyda K; Zelterman D; Hatzis C; Deshpande H; Digiovanna MP; Azodi M; Schwartz PE; Harris LN
Cancer; 2015 Jun; 121(11):1817-26. PubMed ID: 25649370
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.
Jerusalem G; Fasolo A; Dieras V; Cardoso F; Bergh J; Vittori L; Zhang Y; Massacesi C; Sahmoud T; Gianni L
Breast Cancer Res Treat; 2011 Jan; 125(2):447-55. PubMed ID: 21107682
[TBL] [Abstract][Full Text] [Related]
8. TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.
Burris HA; Kurkjian CD; Hart L; Pant S; Murphy PB; Jones SF; Neuwirth R; Patel CG; Zohren F; Infante JR
Cancer Chemother Pharmacol; 2017 Aug; 80(2):261-273. PubMed ID: 28601972
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab.
Andre F; Campone M; O'Regan R; Manlius C; Massacesi C; Sahmoud T; Mukhopadhyay P; Soria JC; Naughton M; Hurvitz SA
J Clin Oncol; 2010 Dec; 28(34):5110-5. PubMed ID: 20975068
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors.
Fury MG; Sherman E; Haque S; Korte S; Lisa D; Shen R; Wu N; Pfister D
Cancer Chemother Pharmacol; 2012 Mar; 69(3):591-8. PubMed ID: 21913034
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).
Huober J; Fasching PA; Hanusch C; Rezai M; Eidtmann H; Kittel K; Hilfrich J; Schwedler K; Blohmer JU; Tesch H; Gerber B; Höß C; Kümmel S; Mau C; Jackisch C; Khandan F; Costa SD; Krabisch P; Loibl S; Nekljudova V; Untch M; Minckwitz Gv
Eur J Cancer; 2013 Jul; 49(10):2284-93. PubMed ID: 23541564
[TBL] [Abstract][Full Text] [Related]
12. A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.
Hollebecque A; Houédé N; Cohen EE; Massard C; Italiano A; Westwood P; Bumgardner W; Miller J; Brail LH; Benhadji KA; Soria JC
Eur J Cancer; 2014 Mar; 50(5):876-84. PubMed ID: 24456794
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancer.
Acevedo-Gadea C; Santin AD; Higgins SA; Urva S; Ratner E; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Abu-Khalaf MM
Int J Gynecol Cancer; 2014 Mar; 24(3):528-33. PubMed ID: 24557436
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
[TBL] [Abstract][Full Text] [Related]
15. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.
Tabernero J; Rojo F; Calvo E; Burris H; Judson I; Hazell K; Martinelli E; Ramon y Cajal S; Jones S; Vidal L; Shand N; Macarulla T; Ramos FJ; Dimitrijevic S; Zoellner U; Tang P; Stumm M; Lane HA; Lebwohl D; Baselga J
J Clin Oncol; 2008 Apr; 26(10):1603-10. PubMed ID: 18332469
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.
Villalona-Calero MA; Weiss GR; Burris HA; Kraynak M; Rodrigues G; Drengler RL; Eckhardt SG; Reigner B; Moczygemba J; Burger HU; Griffin T; Von Hoff DD; Rowinsky EK
J Clin Oncol; 1999 Jun; 17(6):1915-25. PubMed ID: 10561233
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours.
Androulakis N; Kouroussis C; Mavroudis D; Kakolyris S; Souglakos J; Agelaki S; Kalbakis K; Malas K; Pallis A; Samonis G; Georgoulias V
Eur J Cancer; 2002 Oct; 38(15):1992-7. PubMed ID: 12376203
[TBL] [Abstract][Full Text] [Related]
18. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
Papadimitrakopoulou VA; Soria JC; Jappe A; Jehl V; Klimovsky J; Johnson BE
J Thorac Oncol; 2012 Oct; 7(10):1594-601. PubMed ID: 22968184
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer.
Ciunci CA; Perini RF; Avadhani AN; Kang HC; Sun W; Redlinger M; Harlacker K; Flaherty KT; Giantonio BJ; Rosen MA; Divgi CR; Song HK; Englander S; Troxel A; Schnall M; O'Dwyer PJ
Cancer; 2014 Jan; 120(1):77-85. PubMed ID: 24108668
[TBL] [Abstract][Full Text] [Related]
20. A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies.
Wise-Draper TM; Moorthy G; Salkeni MA; Karim NA; Thomas HE; Mercer CA; Beg MS; O'Gara S; Olowokure O; Fathallah H; Kozma SC; Thomas G; Rixe O; Desai P; Morris JC
Target Oncol; 2017 Jun; 12(3):323-332. PubMed ID: 28357727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
